Robust drug target selection
Identifying a robust drug target is a critical early milestone for therapeutic development programs, where mistakes could be disastrous and costly. Understanding if a protein plays a causal disease role is vital, but far from trivial to determine. The unique advantages of combining genomic and proteomic data (“proteogenomics”) can provide unique insights into the likely causal role of any given protein in a specific disease phenotype.
Selected webinars
Dr. Chris Whelan (Chair and Principal Investigator of the UK Biobank – Pharma Proteomics Project) discusses how data from the UK Biobank – Pharma Proteomics Project has revealed new insights into associations between gene variants and protein concentrations enabling new causal biomarkers for diseases to be identified as well as new drug targets with higher probabilities of success.
Selected publications
The integration of genomics and proteomics is driving a new era of discovery and accelerating the identification of new, robust drug targets. Recent articles show how using Olink to measure hundreds or thousands of proteins with high specificity in large cohorts adds a much-needed layer of resolution to genetic data. These studies provide crucial new insights into disease biology and pinpoint causal proteins for confident development of new therapeutic targets.
A flexible platform that accelerates your research
Olink’s scalable technology provides optimized solutions for every stage of the biomarker workflow, from high-throughput discovery through validation and clinical utility.
Get help choosing. Talk to a Specialist.
Olink Explore HT
Measure 5,400+ proteins with proven specificity to gain an understanding of disease at the protein level.
Proteins
5,400+ With proven specificity
Sample
2 µL Plasma, serum & more
Olink Flex
Run individually tailored studies by combining up to 21 biomarkers from our extensive library with minimal sample volume.
Proteins
~200 Pre-validated assays
Sample
1 µL Plasma, serum & more
Olink Target 96
Target specific disease areas or key biological processes with multiplex immunoassay panels.
Proteins
1,100+ On 15 targeted panels
Sample
1 µL Plasma, serum & more
Olink Target 48
Extensively validated and carefully selected biomarkers for a comprehensive view of cytokine signaling and inflammatory processes.
Proteins
89 On 2 panels
Sample
1 µL Plasma, serum & more